>
pdufa.bio

Aglatimagene Besadenovec

Updated ยทnext FDA decision on the calendar

Aglatimagene Besadenovec is a Candel Therapeutics, Inc. program. Its next catalyst is a Readout in Jan 2027. Every date links its source.

CADL catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Candel Therapeutics, Inc. (CADL). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Jan 2027CADL

Questions

When is Aglatimagene Besadenovec's next FDA decision or readout?

The next tracked catalyst for Aglatimagene Besadenovec is a Readout in Jan 2027.

What happened at Aglatimagene Besadenovec's most recent FDA decision?

No FDA decision for Aglatimagene Besadenovec is in our archive yet.

Who makes Aglatimagene Besadenovec?

Candel Therapeutics, Inc. (CADL).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.